Rajan Saggar MD

Pulmonology•Los Angeles, CA

Critical Care Medicine

Assistant Professor, Medicine, UCLA School of Medicine

Join to View Full Profile

10833 LeConte Ave., 37-131 CHSLos Angeles, CA 90095
Phone+1 310-825-8061
Fax+1 310-825-8061

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2007
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 1999 - 2002
Medical College of WisconsinClass of 1999

Certifications & Licensure

CA State Medical License 2002 - 2026
WI State Medical License 2001 - 2003
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation Start of enrollment: 2006 Jan 01
Withdrawn
Phase 3
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Start of enrollment: 2007 Feb 01
Withdrawn
Phase 4
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan Start of enrollment: 2007 Oct 01
Withdrawn
Phase 4
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension Start of enrollment: 2008 Jul 01
Completed
Phase 2
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension Start of enrollment: 2011 Jan 01
Completed
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan Start of enrollment: 2009 Mar 01
Completed
Phase 4
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension Start of enrollment: 2010 Apr 01
Completed
Phase 2
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. Start of enrollment: 2011 Mar 01
Completed
Phase 2
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
Completed
Phase 3
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
Terminated
Phase 3
Pulmonary Hemodynamics During Exercise - Research Network Start of enrollment: 2018 Dec 01
Recruiting
Roles: Contact
Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19 Start of enrollment: 2020 Jul 13
Completed
Not Applicable
Effect of INO in Patients with Submassive and Massive PE Start of enrollment: 2025 Jun 01
WITHDRAWN
PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American So...
Monica Mukherjee, Lawrence G Rudski, Karima Addetia, Jonathan Afilalo, Michele D'Alto
Journal of the American Society of Echocardiography. 2025-03-01
2 citations
Lysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension.
Lloyd D Harvey, Mona Alotaibi, Yi-Yin Tai, Ying Tang, Hee-Jung J Kim
Science. 2025-01-24
Delirium Management Quality Improvement Project to Improve Awareness and Screening in a Medical ICU.
Hirsh Makhija, Kyle Digrande, Omar Awan, Russell G Buhr, Rajan Saggar
Nursing Reports. 2024-12-30

Press Mentions

New Insights and Potential Treatments for Pulmonary HypertensionAugust 21st, 2024
I'm Aware That I'm Rare: The Phaware® PodcastApril 10th, 2024